SCHEMBL4182162

SCHEMBL4182162

COc1ccc(S(=O)(=O)NCCNS(=O)(=O)c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.77
HTT P42858 6/20 0.75
LMNA P02545 4/20 0.75
MAPK1 P28482 3/20 0.75
PDE4A P27815 1/20 0.75
PDE4B Q07343 1/20 0.75
PDE4C Q08493 1/20 0.75
PDE4D Q08499 1/20 0.75
NPSR1 Q6W5P4 1/20 0.69
ALDH1A1 P00352 4/20 0.68
TSHR P16473 3/20 0.68
HSD17B10 Q99714 1/20 0.68
SMN1; SMN2 Q16637 2/20 0.64
POLB P06746 1/20 0.61
CA12 O43570 1/20 0.59
CA9 Q16790 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5169194 0.94 KMT2A (0.69) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL4173056 0.92 KMT2A (0.68) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL7420609 0.92 HTT (0.78) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL9858703 0.89 HTT (0.89) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL4609361 0.88 ALDH1A1 (0.74) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL2791351 0.86 HTT (1.00) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL7596502 0.86 KMT2A (0.64) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL2791185 0.86 HTT (1.00) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL14384038 0.86 KMT2A (0.64) KMT2AHTTLMNAMAPK1PDE4A
SCHEMBL2941926 0.86 MAPK1 (0.65) KMT2AHTTLMNAMAPK1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 US disclosed
US-9096501-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-08-04 US disclosed
US-20140343321-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-11-20 US disclosed
US-8759327-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-06-24 US disclosed
US-8759327-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-06-24 US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090011055-A1 Plasminogen Activator Inhibitor-1 Inhibitors And Methods Of Use Thereof To Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2009-01-08 US disclosed
US-20090011055-A1 Plasminogen Activator Inhibitor-1 Inhibitors And Methods Of Use Thereof To Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2009-01-08 US disclosed
WO-2008131047-A2 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2008-10-30 WO disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism SERPINE1, PLAT, SERPINB1 KMT2A 3410/4885HTT 1212/4885LMNA 1156/4885
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A KMT2A 3729/4885HTT 935/4885LMNA 3674/4885
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM SERPINE1, PLAT, SERPINB1 KMT2A 3410/4885HTT 1212/4885LMNA 1156/4885
US-20140343321-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism SERPINE1, PLAT, SERPINB1 KMT2A 3410/4885HTT 1212/4885LMNA 1156/4885
US-20090011055-A1 Plasminogen Activator Inhibitor-1 Inhibitors And Methods Of Use Thereof To Modulate Lipid Metabolism SERPINE1, PLAT, SERPINB1 KMT2A 3410/4885HTT 1212/4885LMNA 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.